
|Articles|November 21, 2007
Schering-Plough and Organon merger finalized
Schering-Plough/Organon merger passes antitrust scrutiny and is completed
Advertisement
The Federal Trade Commission has cleared Schering-Plough's acquisition of Organon BioSciences N.V. from Akzo Nobel N.V. with no requirement for any divestitures in human health products. So Schering-Plough announced the merger is now complete. According to Schering-Plough's CEO Fred Hassan, Organon brings to the table two important pharmaceutical franchises, women's health and central nervous system products. In addition, it has several promising phase III compounds in development.
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Model Finds Weight Regain After Stopping Semaglutide or Tirzepatide
2
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
3
Investigational Oral AD109 Reduces Sleep Apnea Severity by 44%
4
Zepbound Lowers Health Care Costs in Older Adults With Obesity
5







































